within Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH05_Dupilumab;

model Dupilumab
  extends Pharmacolibrary.Drugs.ATC.D.D11AH05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D11AH05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dupilumab is a fully human monoclonal antibody that inhibits signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) by binding to the IL-4 receptor alpha subunit. It is used in the treatment of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, and is an FDA and EMA approved biologic drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported from adult patients with atopic dermatitis; population PK analyses evaluated after subcutaneous administration in healthy or affected subjects.</p><h4>References</h4><ol><li><p>Li, Z, et al., &amp; Swanson, BN (2020). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. <i>Clinical pharmacology in drug development</i> 9(6) 742–755. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.798&quot;>10.1002/cpdd.798</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32348036/&quot;>https://pubmed.ncbi.nlm.nih.gov/32348036</a></p></li><li><p>Cohen, YZ, et al., &amp; Xu, C (2022). Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe. <i>Clinical pharmacology in drug development</i> 11(5) 675–681. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1073&quot;>10.1002/cpdd.1073</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35278283/&quot;>https://pubmed.ncbi.nlm.nih.gov/35278283</a></p></li><li><p>Kamal, MA, et al., &amp; Arima, K (2022). Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis. <i>Clinical and translational science</i> 15(10) 2342–2354. DOI:<a href=&quot;https://doi.org/10.1111/cts.13363&quot;>10.1111/cts.13363</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35986664/&quot;>https://pubmed.ncbi.nlm.nih.gov/35986664</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dupilumab;
